title: Pimecrolimus: a new choice in the treatment of vitiligo?
authors.forename: A
authors.initials: A
authors.lastname: Eryilmaz
authors.forename: D
authors.initials: D
authors.lastname: Seçkin
authors.forename: M
authors.initials: M
authors.lastname: Baba
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002990:Clobetasol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014820:Vitiligo / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D003879:Dermatologic Agents; C117268:pimecrolimus; D002990:Clobetasol; D016559:Tacrolimus